Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 9, 2015

View Archived Issues

Endonovo Therapeutics announces new bioelectronic-based platforms for regenerative medicine

Meiji Seika begins two new clinical trials of safinamide for Parkinson's disease

CEVEC and CellGenix establish collaboration and license agreement for CAPGo technology

Horizon Discovery and Servier enter agreement on anticancer kinase inhibitors

Samumed reports DYRK1A inhibitors

Lion Biotechnologies obtains license from NIH to TIL therapy in additional indications

Genocea reports durability data from 6-month analysis of phase II GEN-003 trial

Mixed Hantaan/Puumala virus DNA vaccine shows safety and immunogenicity

Indoximod/ipilimumab combination therapy well tolerated in phase Ib study

Novel multiple ligand trap increases muscle and bone mass

Antibe Therapeutics to move into regenerative medicine through Citagenix acquisition

Lilly's abemaciclib receives FDA breakthrough therapy designation

CMV vaccine elicits humoral and cellular immune responses in animal models

Neurocrine reports data from phase III Kinect 3 study of NBI-98854

Charles River Laboratories announces three discovery collaborations

Bristol-Myers Squibb discloses NS5B inhibitors

Boehringer Ingelheim reports phase II data for BI-655066 in psoriasis

Capella Therapeutics announces EGFR inhibitors

Bayer patents Wnt signaling inhibitors

Prothena presents anti-LAMA4 MAbs

Cell culture-derived influenza vaccine shows excellent immunogenicity

FDA grants 12-year exclusivity to Salix and Pharming's Ruconest

City of Hope receives NIDDK grant to study epigenetic changes in diabetes

ECTRIMS 2015: MEDI-551 is safe in multiple sclerosis patients; phase I results

Altor receives NCI grant to support development of ALT-803 for NHL

Abcam launches anti-PD-L1 antibody research tool

NIH awards grant to Circulomics to advance Nanobind nucleic acid extraction technology

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...